BR0209684A - Derivado de magainina e sais farmaceuticamente aceitáveis produzidos a partir do mesmo, método para a produção do derivado de magainina e uso do derivado de magainina e sais farmaceuticamente aceitáveis - Google Patents

Derivado de magainina e sais farmaceuticamente aceitáveis produzidos a partir do mesmo, método para a produção do derivado de magainina e uso do derivado de magainina e sais farmaceuticamente aceitáveis

Info

Publication number
BR0209684A
BR0209684A BR0209684-6A BR0209684A BR0209684A BR 0209684 A BR0209684 A BR 0209684A BR 0209684 A BR0209684 A BR 0209684A BR 0209684 A BR0209684 A BR 0209684A
Authority
BR
Brazil
Prior art keywords
pharmaceutically acceptable
acceptable salts
magainin
magainin derivative
derivative
Prior art date
Application number
BR0209684-6A
Other languages
English (en)
Other versions
BRPI0209684B8 (pt
BRPI0209684B1 (pt
Inventor
Yukun Sun
Dengxi Wu
Zhiyong Zhu
Original Assignee
Shanghai Huayi Biotech Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Huayi Biotech Lab filed Critical Shanghai Huayi Biotech Lab
Publication of BR0209684A publication Critical patent/BR0209684A/pt
Publication of BRPI0209684B1 publication Critical patent/BRPI0209684B1/pt
Publication of BRPI0209684B8 publication Critical patent/BRPI0209684B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/463—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from amphibians
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

"DERIVADO DE MAGAININA E SAIS FARMACEUTICAMENTE ACEITáVEIS PRODUZIDOS A PARTIR DO MESMO, MéTODO PARA A PRODUçãO DO DERIVADO DE MAGAININA E USO DO DERIVADO DE MAGAININA E SAIS FARMACEUTICAMENTE ACEITáVEIS". A presente invenção refere-se a uma variedade de derivados de magainina e aos sais farmaceuticamente aceitáveis produzidos a partir dos mesmos, com os derivados tendo seq³ências conforme mostradas abaixo: Gly-Ile-Gly-Lys-Phe-Leu-His-Ser-Ala-Lys-LysPhe-Gly-Lys-Ala-Phe-Val -Gly-Glu-Ile-X-Asn-Y-OH na qual: X é an resíduo de amino ácido selecionado a partir do grupo consistindo de Met, Ile e Leu, Y é a combinação de dois resíduos de amino ácidos selecionados a partir do grupo consistindo de Ser, Lys, Ile, Arg e Leu. Os derivados de acordo com a presente invenção têm a mesma ou uma maior atividade anti-microbial quando comparados com aquela da magainina ocorrendo naturalmente. Os mesmos são facilmente produzidos por síntese de fase sólida e, mais facilmente, através de técnicas de bioengenharia.
BRPI0209684A 2001-05-10 2002-05-08 derivado de magainina e sais farmaceuticamente aceitáveis produzidos a partir do mesmo, método para a produção do derivado de magainina e uso do derivado de magainina e sais farmaceuticamente aceitáveis BRPI0209684B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CNB011128550A CN1158304C (zh) 2001-05-10 2001-05-10 蛙皮抗菌肽衍生物
PCT/CN2002/000317 WO2003016339A1 (en) 2001-05-10 2002-05-08 A frog skin antibacterial peptide derivative

Publications (3)

Publication Number Publication Date
BR0209684A true BR0209684A (pt) 2004-07-13
BRPI0209684B1 BRPI0209684B1 (pt) 2016-08-30
BRPI0209684B8 BRPI0209684B8 (pt) 2021-05-25

Family

ID=4659602

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0209684A BRPI0209684B8 (pt) 2001-05-10 2002-05-08 derivado de magainina e sais farmaceuticamente aceitáveis produzidos a partir do mesmo, método para a produção do derivado de magainina e uso do derivado de magainina e sais farmaceuticamente aceitáveis

Country Status (9)

Country Link
US (2) US7232800B2 (pt)
EP (1) EP1386928B1 (pt)
JP (1) JP4194941B2 (pt)
KR (1) KR100902209B1 (pt)
CN (1) CN1158304C (pt)
AU (1) AU2002257498B2 (pt)
BR (1) BRPI0209684B8 (pt)
CA (1) CA2446848C (pt)
WO (1) WO2003016339A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1158304C (zh) * 2001-05-10 2004-07-21 上海华谊生物技术有限公司 蛙皮抗菌肽衍生物
US7550426B2 (en) * 2005-05-18 2009-06-23 Ghc Research Development Corporation Acetylated therapeutic procytotoxins
CN100575359C (zh) * 2006-04-17 2009-12-30 中国科学院成都生物研究所 一种无指盘臭蛙抗菌肽及其用途
CN100522993C (zh) * 2006-05-30 2009-08-05 中国科学院昆明动物研究所 无指盘臭蛙抗菌肽
CN101182360B (zh) * 2007-10-08 2010-07-07 国家海洋局第一海洋研究所 一种具有抗菌功能的融合蛋白及其应用
CN101928340A (zh) * 2009-12-24 2010-12-29 深圳市圣西马生物技术有限公司 一组抗菌肽衍生物及其应用
CN102796177A (zh) * 2012-08-13 2012-11-28 中国科学院烟台海岸带研究所 一种改造体抗菌肽及其制备方法和应用
CN102786583B (zh) * 2012-08-13 2014-03-19 中国科学院烟台海岸带研究所 一种昆嵛林蛙改造体抗菌肽及其制备方法和应用
GB201409451D0 (en) 2014-05-28 2014-07-09 Ipabc Ltd Antimicrobial preparations, methods for preparing the same and uses thereof to combat microorganisms
WO2018100408A1 (en) * 2016-11-30 2018-06-07 Sasinapas Co.,Ltd. Modified peptides
CN106749594B (zh) 2016-12-27 2020-02-14 王天放 包含f1、f3多肽的药物组合物及其在治疗hpv感染疾病中的应用
US11325955B2 (en) * 2017-07-19 2022-05-10 Dana-Farber Cancer Institute, Inc. Stabilized anti-microbial peptides for the treatment of antibiotic-resistant bacterial infections
CN110042138B (zh) * 2019-04-10 2020-12-29 常熟理工学院 一种林蛙油抗氧化肽组分的制备方法及其分离方法与用途
CN116134045A (zh) * 2021-09-03 2023-05-16 深圳千越生物科技有限公司 抗菌肽或肽衍生物、替换体以及其组合物、制备方法和应用
CN117643563B (zh) * 2024-01-29 2024-03-29 广州首漾医药生物科技有限公司 一种抑菌除螨膏霜及制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5912231A (en) * 1989-07-07 1999-06-15 Scripps Clinic And Research Foundation Substitution analogues of magainin peptides
US5792831A (en) * 1990-02-08 1998-08-11 Magainin Pharmaceuticals Inc. Analogues of magainin peptides containing D-amino acids
US5654274A (en) * 1992-06-01 1997-08-05 Magainin Pharmaceuticals, Inc. Biologically active peptides having N-terminal substitutions
US5589364A (en) * 1994-07-29 1996-12-31 Magainin Pharmaceuticals Inc. Recombinant production of biologically active peptides and proteins
US6461834B1 (en) * 1998-11-06 2002-10-08 Bionebraska, Inc. Clostripain catalyzed amidation of peptides
EP1076066A1 (en) * 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
CN1158304C (zh) * 2001-05-10 2004-07-21 上海华谊生物技术有限公司 蛙皮抗菌肽衍生物

Also Published As

Publication number Publication date
EP1386928A4 (en) 2005-04-13
CA2446848A1 (en) 2003-02-27
US20070166790A1 (en) 2007-07-19
KR20030094388A (ko) 2003-12-11
WO2003016339A1 (en) 2003-02-27
BRPI0209684B8 (pt) 2021-05-25
US20040197864A1 (en) 2004-10-07
CA2446848C (en) 2013-09-10
CN1158304C (zh) 2004-07-21
EP1386928A1 (en) 2004-02-04
AU2002257498B2 (en) 2007-10-25
JP2005502663A (ja) 2005-01-27
EP1386928B1 (en) 2015-10-14
KR100902209B1 (ko) 2009-06-11
BRPI0209684B1 (pt) 2016-08-30
CN1363558A (zh) 2002-08-14
US7232800B2 (en) 2007-06-19
JP4194941B2 (ja) 2008-12-10

Similar Documents

Publication Publication Date Title
BR0209684A (pt) Derivado de magainina e sais farmaceuticamente aceitáveis produzidos a partir do mesmo, método para a produção do derivado de magainina e uso do derivado de magainina e sais farmaceuticamente aceitáveis
CN103124724B (zh) Lsd1的基于芳基环丙胺的脱甲基酶抑制剂及其医疗用途
CA2655116C (en) Peptide fragments for inducing synthesis of extracellular matrix proteins
BR0209685A (pt) Derivado de um peptìdeo insulinotrópico e sais farmaceuticamente aceitáveis produzidos a partir do mesmo, método de produção de derivado de peptìdeo insulinotrópico e uso de um derivado de peptìdeo insulinotrópico e de sais farmaceuticamente aceitáveis
DK1086124T3 (da) Nye cyclosporiner
BR0211888A (pt) Materiais e métodos para promoção de reparo de tecido nervoso
EA201270505A1 (ru) Производные иминотиадиазиндиоксида в качестве ингибиторов bace, композиции на их основе, и их применение
NZ591130A (en) Compositions comprising a PD-1 antagonists and cyclophosphamide and methods of use thereof
EA199700267A1 (ru) Применение фумагиллола и его производных для приготовления антиинфекционных интестинальных препаратов и фармацевтическая композиция на их основе
AR025307A1 (es) Compuesto de liberacion sostenida de un peptido, microparticulas, composicion farmaceutica y el uso de dicho compuesto para la fabricacion de un medicamento
CA2417050A1 (en) Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
WO2006053039A3 (en) Hydroxybenzoate salts of metanicotine compounds
RU94042240A (ru) Антагонисты рецепторов возбужденных аминокислот, способ получения, промежуточные соединения, фармацевтическая композиция
EA200400762A1 (ru) Новые соединения, их использование в медицине, способ их изготовления и содержащие их фармацевтические композиции
DK1274411T3 (da) Phenylethylaminer og ringkondenserede varianter som prodrugs af catecholaminer og deres anvendelse
DOP2002000512A (es) Sales de acido succinato de 5,7,14-triazatetraciclo [10.3.1.0² ¹¹.04,9] hexadeca-2 (11),3,5,7,9-pentaeno y composiciones farmaceuticas de las mismas
EP2540735A3 (en) Template-fixed beta-hairpin peptidomimetics with CXCR4 antagonizing activity
BR0211739A (pt) Novas formas polimórficas cristalinas de cloridrato de lercanidipina e processo para preparação das mesmas
EE200000014A (et) (+)-nortsisapriidaluse valmistamismeetod, (+)-nortsisapriid, selle farmatseutiliselt vastuvõetav happe liitsool ja nende kasutamine, farmatseutiline kompositsioon ja selle valmistamismeetod ning vaheühend
DK0669912T3 (da) N-(3-Piperidinylcarbonyl)-beta-alaninderivater som PAF-antagonister
EA200201158A1 (ru) Бициклические циклогексиламины и их применение в качестве антагонистов nmda-рецепторов
BR0214695A (pt) Derivados de pirazol com anel fundido
CY1105550T1 (el) Μεμνο-πεπτιδια, μια διαδικασια για την παρασκευη και τη χρηση τους
PT84620B (pt) Processo para a preparacao de novos compostos relacionados com a espergualina
WO2018200571A1 (en) Substituted 2,3-dihydro-1h-indene analogs and methods using same

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B25D Requested change of name of applicant approved

Owner name: SHANGHAI BENEMAE PHARMACEUTICAL COMPANY LIMITED (C

B25D Requested change of name of applicant approved

Owner name: SHANGHAI BENEMAE PHARMACEUTICAL CORPORATION (CN)

B25G Requested change of headquarter approved

Owner name: SHANGHAI BENEMAE PHARMACEUTICAL CORPORATION (CN)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 30/08/2016, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/05/2002 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 08/05/2022